BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 37,000 Shares

Key Points

• CEO insider sale: Ugur Sahin sold 37,000 BioNTech shares at an average price of $99.20, generating $3.67 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his direct ownership by 4.73%.
• Sahin also sold shares in three other recent transactions, bringing the reported sales to 149,500 shares worth approximately $15.1 million. He retained 744,709 shares valued at about $73.9 million after the featured sale.
• Business and analyst backdrop: BioNTech’s latest quarterly results missed estimates, with revenue down 59.5% year over year, while the stock traded near $98. Analysts maintained an overall “Moderate Buy” consensus with a $126 average price target, despite some downgrades to sell.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 37,000 shares of BioNTech stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00. Following the completion of the transaction, the chief executive officer directly owned 744,709 shares in the company, valued at approximately $73,875,132.80. This trade represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Down 0.5%

BioNTech stock traded down $0.53 during midday trading on Wednesday, reaching $98.13. The stock had a trading volume of 706,871 shares, compared to its average volume of 1,112,188. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a market cap of $24.82 billion, a price-to-earnings ratio of -12.53 and a beta of 1.29. The firm's fifty day simple moving average is $96.94 and its two-hundred day simple moving average is $95.55.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech's revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.60) earnings per share. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in shares of BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock worth $653,000 after acquiring an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter valued at about $167,000. Russell Investments Group Ltd. raised its stake in shares of BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company's stock valued at $1,178,000 after acquiring an additional 11,064 shares in the last quarter. Natixis bought a new position in shares of BioNTech in the 2nd quarter valued at approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company's stock worth $52,416,000 after purchasing an additional 13,788 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BNTX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of BioNTech in a research note on Monday, July 6th. Canaccord Genuity Group lowered their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a research note on Monday, August 31st. Citigroup dropped their target price on BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Berenberg Bank decreased their price target on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $126.00.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.